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Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312S296all patients are alive. At 18 months after transplantation, one
patient experienced progressive pancytopenia, requiring red
blood cell transfusion, in spite of the full donor chiemrism
both in the bone marrow and peripheral blood T cells.
Chimerism analysis of the peripheral blood T cells was
analyzed later than 6 months post-transplant, showing
mixed chimerism in 3 patients with stable hematopoiesis.
The recovery of menstruationwas observed in all 4 evaluable
young female patients at 3, 7, 8, and 9 months after trans-
plantation, respectively.
Conclusion: These results suggest that this regimen could be
a safe and effective conditioning regimen of allogeneic HSCT
for SAA both from sibling and unrelated donor. However,
long-term follow-up is needed to further evaluate the
dynamics of T-cell chimerism and the incidence of late-onset
graft failure.373
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Background: Case reports of allogeneic hematopoietic stem
cell transplantation (HSCT) following liver transplantation in
children with immunodeﬁciencies have been published in
the past and have described correction of the underlying
disease.
The objective of this study is to report the clinical
outcomes of a series of pediatric recipients of allogeneic
hematopoietic stem cell transplantation following previous
liver transplantation.
Method: Retrospective analysis of 8 patients who underwent
HSCT following previous liver transplantation between
2003-2012 at a single institution.
Results: Seven patients (4 males and 3 females) underwent
orthotopic whole liver transplantation for fulminant or
chronic liver disease of unknown etiology; 1 male patient
received segmental liver transplantation for alpha-1 anti-
trypsin deﬁciency. Six of 8 patients underwent reduced
intensity conditioning while 2/8 received myeloablative
conditioning prior to allogeneic hematopoietic stem cell
transplantation. Seven patients received unrelated donor
HSCT and 1 patient had a matched sibling donor. Seven
patients were later diagnosed with hemophagocytic lym-
phohistiocytosis (HLH), 5/7 with negative genetic studies for
known genes of HLH, including one with Epstein Barr Virus-
induced HLH, 1 patient with X-linked inhibitor of apoptosis
deﬁciency-induced HLH, 1 patient with combined immune
deﬁciency. All patients engrafted. Two patients died before
day 100, 1 patient has been lost of follow up more than 2
years after HSCT, 4 patients are alive for +3 years with good
life quality, and one patient has recently been transplanted.
Two patients with mild or no transaminitis still receive lowdose of immune suppressive drugs for liver transplant as
directed by their surgeons.
Conclusion: HLHmay present with fulminant or cryptogenic
liver failure requiring correction with orthotopic liver
transplantation prior bone marrow transplantation. Ortho-
topic liver transplantation followed by unrelated donor HSCT
using reduced intensity conditioning can lead to relevant
immune reconstitution with stably improved quality of life
and resolution of HLH.374
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Background: There is no standard of care for patients (pts)
with relapsed acute myelogenous leukemia (AML) after
allogeneic hematopoietic cell transplantation (allo HCT).
Outcome is dismal with 2-year overall survival (OS) of< 10%.
Rapid immunosuppression taper to induce graft-versus-
leukemia effect, cell therapy (CT)  chemotherapy, or che-
motherapy(ChT) alone have all been attempted, however,
there is paucity of comparative analysis examining the
outcomes of these strategies.
Methods: To evaluate the efﬁcacy of different approaches,
we conducted a single-institution retrospective analysis
comparing the efﬁcacy of different therapeutic options in
these pts. We assessed the impact of CT versus ChT on their
response and outcomes using uni- and multivariate analysis.
Results: We report the outcomes of 85 adult AML pts;
median age was 50 (range: 19-69) years relapsed post allo
HCT. Median time from transplant to relapse was 4.3 (range,
0.6-45) months (mo). Twenty eight (32%) pts received ChT
with either hypomethylating agents (HMA) or other ChT; 21
(24%) pts received CT, including donor lymphocyte infusion
(DLI) or CD34+ stem cells  ChT; 36 (42%) pts received
supportive care only. The median post HCT follow up of
surviving pts was 9 (range: 2-85) mo. Complete remission
(CR) rate for all pts who received any therapywas 40% (62% of
CTgroup compared to 22% receiving ChT alone (P¼ .002)). CT
produced higher CR rate compared to ChT alone (P ¼ .007).
The median time to relapse after achieving a second CR post
therapy for all pts was 13mowith 14% , 40% and 70% relapsed
by 6, 12 and 24 months respectively. Median OS after relapse
for all pts was 3.7 mo with the best outcome noted in the CT
group at 10.2 mo compared to 3.6 mo for those received ChT
alone. Univariate analysis showed that receiving either CT or
ChT compared to no therapy improved OS (P < .0001);
however there was no difference between CT and ChT (P ¼
.06). Multivariate analysis showed that the pre-HCT cytoge-
netics, CIBMTR risk score, comorbidity index and donor type
had no impact on the CR rate or outcomes. However, CT was
the only signiﬁcant covariate over ChT (P ¼ .0071).
Conclusions: These data suggest that pts who are able to
receive CT in addition to ChT have the best chance of
achieving CR. Future approaches should focus on prospec-
tively combining these modalities to improve OS in AML pts
relapsing post allo HCT.
